ERBB2 and triple-negative breast carcinoma: Objective: This study focuses on the omission of SLNB in elderly patients aged 80 and older with HER2-positive (HER2+) or triple-negative breast cancer (TNBC) who are clinically node-negative (cN0), comparing outcomes to other relevant studies.